Cargando…
PEGylated drugs in rheumatology—why develop them and do they work?
Lack of efficacy and drug-related adverse effects are important reasons for the discontinuation of treatment in patients with rheumatic diseases. The development of new biologic therapies seeks to address these problems by specifically targeting the pathogenic mechanisms of disease. Most current bio...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930883/ https://www.ncbi.nlm.nih.gov/pubmed/23962623 http://dx.doi.org/10.1093/rheumatology/ket278 |